• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

健康供者应用大剂量粒细胞集落刺激因子动员外周血造血祖细胞时最佳的单采时机。

Optimal timing of apheresis for the efficient mobilization of peripheral blood progenitor cells recruited by high-dose granulocyte colony-stimulating factor in healthy donors.

机构信息

Department of Hematology, Fukushima Medical University, Fukushima, Japan.

Department of Hematology, Fukushima Medical University, Fukushima, Japan.

出版信息

Transfus Apher Sci. 2020 Jun;59(3):102737. doi: 10.1016/j.transci.2020.102737. Epub 2020 Feb 5.

DOI:10.1016/j.transci.2020.102737
PMID:32051100
Abstract

Predictors of peripheral blood stem cell (PBSC) yield can potentially improve the comfort, safety, and efficacy of CD34+ cell collection from donors treated with recombinant human granulocyte colony-stimulating factor (G-CSF). We investigated 181 apheresis procedures on 109 healthy allogeneic donors to identify factors correlating with efficient PBSC collection. Apheresis started on Day 4 or 5 and continued up to Day 6 of G-CSF administration. CD34+ cell yields on Days 4 and 5 were comparable, and significantly higher than on Day 6. This suggests that starting apheresis on Day 4 rather than Day 5 may be preferable, to reduce G-CSF exposure and optimize yield, even if multi-day collection is required. More CD34+ cells were collected from male and cytomegalovirus (CMV)-seronegative donors than from female and CMV-seropositive donors, respectively. The yields of CD34+ cells were similarly high in both male and female donors aged 20-29 years; yields decreased in female donors in their thirties, and were comparably low in both male and female donors in their forties and thereafter. These findings should guide decision-making about when to begin apheresis, and encourage careful consideration of donor factors such as gender, age, and CMV serostatus when collecting PBSCs.

摘要

外周血造血干细胞(PBSC)产量的预测因子可以潜在地提高接受重组人粒细胞集落刺激因子(G-CSF)治疗的供者的舒适度、安全性和采集 CD34+细胞的疗效。我们研究了 109 名健康异基因供者的 181 次单采程序,以确定与有效 PBSC 采集相关的因素。单采于 G-CSF 给药的第 4 天或第 5 天开始,并持续到第 6 天。第 4 天和第 5 天的 CD34+细胞产量相当,且显著高于第 6 天。这表明,与第 5 天相比,第 4 天开始单采可能更可取,以减少 G-CSF 的暴露并优化产量,即使需要多日采集。与女性和巨细胞病毒(CMV)阳性供者相比,男性和 CMV 阴性供者分别采集到更多的 CD34+细胞。20-29 岁的男性和女性供者的 CD34+细胞产量同样高;30 岁的女性供者的产量下降,40 岁及以上的男性和女性供者的产量相当低。这些发现应该指导何时开始单采的决策,并鼓励在采集 PBSC 时仔细考虑供者的因素,如性别、年龄和 CMV 血清状态。

相似文献

1
Optimal timing of apheresis for the efficient mobilization of peripheral blood progenitor cells recruited by high-dose granulocyte colony-stimulating factor in healthy donors.健康供者应用大剂量粒细胞集落刺激因子动员外周血造血祖细胞时最佳的单采时机。
Transfus Apher Sci. 2020 Jun;59(3):102737. doi: 10.1016/j.transci.2020.102737. Epub 2020 Feb 5.
2
High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection.高剂量与标准剂量非格司亭(重组人粒细胞集落刺激因子)用于动员异基因供者外周血祖细胞及CD34(+)免疫选择
J Clin Oncol. 1999 Jul;17(7):2160-72. doi: 10.1200/JCO.1999.17.7.2160.
3
Predictors for successful PBSC collection on the fourth day of G-CSF-induced mobilization in allogeneic stem cell donors.异基因干细胞供者在粒细胞集落刺激因子诱导动员第4天成功采集外周血干细胞的预测因素。
J Clin Apher. 2017 Dec;32(6):397-404. doi: 10.1002/jca.21528. Epub 2017 Jan 31.
4
Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells.粒细胞集落刺激因子对正常个体的治疗:供者体验及其对外周血CD34+细胞计数和外周血干细胞采集的影响
Transfusion. 1996 Jul;36(7):601-10. doi: 10.1046/j.1537-2995.1996.36796323059.x.
5
Analysis of stem cell apheresis products using intermediate-dose filgrastim plus large volume apheresis for allogeneic transplantation.使用中剂量非格司亭加大量单采术对异基因移植的干细胞单采产物进行分析。
Ann Hematol. 2001 Apr;80(4):201-8. doi: 10.1007/s002770100289.
6
Analysis of apheresis content of progenitor cell collections from normal donors to whom granulocyte-colony-stimulating factor is administered.对接受粒细胞集落刺激因子的正常供者祖细胞采集物的单采成分分析。
Transfusion. 1996 Nov-Dec;36(11-12):943-7. doi: 10.1046/j.1537-2995.1996.36111297091734.x.
7
Collection of peripheral blood progenitor cells on Day 4 is feasible and effective while reducing granulocyte-colony-stimulating factor exposure to healthy donors.在第4天采集外周血祖细胞是可行且有效的,同时减少了健康供体接受粒细胞集落刺激因子的暴露。
Transfusion. 2015 Jun;55(6):1269-74. doi: 10.1111/trf.13002. Epub 2015 Feb 3.
8
Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors.1 天内采集外周血造血祖细胞与 2 天相比,可降低无关供者的供者毒性。
Biol Blood Marrow Transplant. 2020 Jun;26(6):1210-1217. doi: 10.1016/j.bbmt.2020.02.011. Epub 2020 Feb 20.
9
Prediction of number of apheresis procedures necessary in healthy donors to attain minimally required peripheral blood CD34+ cells.预测健康供者中需要进行多少次单采术以获得最小外周血 CD34+细胞需求量。
Transfusion. 2009 Nov;49(11):2384-9. doi: 10.1111/j.1537-2995.2009.02314.x. Epub 2009 Jul 17.
10
Efficacy of the mobilization of peripheral blood stem cells by granulocyte colony-stimulating factor in pediatric donors.粒细胞集落刺激因子动员儿科供者外周血干细胞的疗效
Cancer Res. 1999 Jul 15;59(14):3321-4.

引用本文的文献

1
Population Pharmacokinetic-Pharmacodynamic Modeling of Granulocyte Colony-Stimulating Factor to Optimize Dosing and Timing for CD34 Cell Harvesting.粒细胞集落刺激因子的群体药代动力学-药效学建模以优化CD34细胞采集的给药剂量和时间。
Clin Transl Sci. 2025 Jan;18(1):e70121. doi: 10.1111/cts.70121.
2
Single Apheresis Session on the 4th Day of Granulocyte Colony-Stimulating Factor Administration Seems Convenient to Collect Enough Peripheral Blood Stem Cells from Healthy Donors.在粒细胞集落刺激因子给药第4天进行单次单采术似乎便于从健康供体采集足够的外周血干细胞。
Transfus Med Hemother. 2024 Jun 4;51(6):414-423. doi: 10.1159/000538457. eCollection 2024 Dec.
3
Stem Cells Collection and Mobilization in Adult Autologous/Allogeneic Transplantation: Critical Points and Future Challenges.
成人自体/异体移植中的干细胞采集和动员:关键点和未来挑战。
Cells. 2024 Mar 28;13(7):586. doi: 10.3390/cells13070586.